Fmr LLC Regenxbio Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Regenxbio Inc. stock. As of the latest transaction made, Fmr LLC holds 993 shares of RGNX stock, worth $12,442. This represents 0.0% of its overall portfolio holdings.

Number of Shares

993

Previous 1,510 34.24%

Holding current value

$12,442

Previous $31,000 64.52%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$11.51 - $21.53 $5,950 - $11,131	-517 Reduced 34.24%	993 $11,000
Q1 2024 May 13, 2024	SELL	$12.17 - $24.61 $7,155 - $14,470	-588 Reduced 28.03%	1,510 $31,000
Q4 2023 Feb 13, 2024	SELL	$12.89 - $20.82 $2,668 - $4,309	-207 Reduced 8.98%	2,098 $37,000
Q3 2023 Nov 13, 2023	BUY	$16.46 - $19.99 $4,855 - $5,897	295 Added 14.68%	2,305 $37,000
Q2 2023 Aug 11, 2023	SELL	$17.23 - $21.71 $2,067 - $2,605	-120 Reduced 5.63%	2,010 $40,000
Q1 2023 May 11, 2023	SELL	$18.08 - $24.55 $536,216 - $728,103	-29,658 Reduced 93.3%	2,130 $40,000
Q4 2022 Feb 13, 2023	BUY	$20.4 - $24.73 $2,550 - $3,091	125 Added 0.39%	31,788 $720,000
Q3 2022 Nov 10, 2022	BUY	$22.29 - $35.04 $1,582 - $2,487	71 Added 0.22%	31,663 $837,000
Q2 2022 Aug 12, 2022	BUY	$19.35 - $35.04 $399,829 - $724,031	20,663 Added 189.07%	31,592 $780,000
Q1 2022 May 13, 2022	BUY	$24.62 - $34.31 $179,159 - $249,673	7,277 Added 199.26%	10,929 $363,000
Q4 2021 Feb 14, 2022	SELL	$30.19 - $40.28 $1.6 Million - $2.13 Million	-52,980 Reduced 93.55%	3,652 $119,000
Q3 2021 Nov 15, 2021	BUY	$29.09 - $45.68 $1.21 Million - $1.9 Million	41,492 Added 274.06%	56,632 $2.37 Million
Q2 2021 Aug 13, 2021	BUY	$32.46 - $40.48 $491,444 - $612,867	15,140 New	15,140 $588,000

Others Institutions Holding RGNX

# of Institutions

191

Shares Held

43.5M

Call Options Held

58.9K

Put Options Held

58.4K

View Full List

About REGENXBIO Inc.

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $542M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

More about RGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account